1. Home
  2. ARMP vs INLX Comparison

ARMP vs INLX Comparison

Compare ARMP & INLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARMP
  • INLX
  • Stock Information
  • Founded
  • ARMP N/A
  • INLX 1996
  • Country
  • ARMP United States
  • INLX United States
  • Employees
  • ARMP N/A
  • INLX N/A
  • Industry
  • ARMP Biotechnology: Biological Products (No Diagnostic Substances)
  • INLX EDP Services
  • Sector
  • ARMP Health Care
  • INLX Technology
  • Exchange
  • ARMP Nasdaq
  • INLX Nasdaq
  • Market Cap
  • ARMP 52.1M
  • INLX 60.5M
  • IPO Year
  • ARMP N/A
  • INLX N/A
  • Fundamental
  • Price
  • ARMP $1.23
  • INLX $13.13
  • Analyst Decision
  • ARMP Strong Buy
  • INLX
  • Analyst Count
  • ARMP 1
  • INLX 0
  • Target Price
  • ARMP $7.00
  • INLX N/A
  • AVG Volume (30 Days)
  • ARMP 30.3K
  • INLX 6.9K
  • Earning Date
  • ARMP 05-06-2025
  • INLX 05-13-2025
  • Dividend Yield
  • ARMP N/A
  • INLX N/A
  • EPS Growth
  • ARMP N/A
  • INLX N/A
  • EPS
  • ARMP N/A
  • INLX N/A
  • Revenue
  • ARMP $5,174,000.00
  • INLX $18,018,373.00
  • Revenue This Year
  • ARMP $8.43
  • INLX $8.12
  • Revenue Next Year
  • ARMP N/A
  • INLX N/A
  • P/E Ratio
  • ARMP N/A
  • INLX N/A
  • Revenue Growth
  • ARMP 14.24
  • INLX 6.70
  • 52 Week Low
  • ARMP $0.90
  • INLX $5.85
  • 52 Week High
  • ARMP $3.45
  • INLX $16.50
  • Technical
  • Relative Strength Index (RSI)
  • ARMP 39.22
  • INLX 52.55
  • Support Level
  • ARMP $1.11
  • INLX $12.58
  • Resistance Level
  • ARMP $1.30
  • INLX $13.39
  • Average True Range (ATR)
  • ARMP 0.14
  • INLX 0.66
  • MACD
  • ARMP 0.01
  • INLX -0.06
  • Stochastic Oscillator
  • ARMP 42.86
  • INLX 26.24

About ARMP Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.

About INLX Intellinetics Inc.

Intellinetics Inc is a document service and solutions software company serving both the small-to-medium business and governmental sectors. The company's digital transformation products and services are provided through two reporting segments: Document Management and Document Conversion. The Document Management segment consists of solutions involving software platforms, which allow customers to capture and manage all documents across operations such as scanned hard-copy documents and all digital documents including those from Microsoft Office 365, digital images, audio, video, and emails. The company's Document Conversion offerings aid clients as a part of their overall document to convert documents from one medium to another. Majority of revenue is from Document Conversion Segment.

Share on Social Networks: